![Christopher Aker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Aker
Consejero General en REGULUS THERAPEUTICS INC. .
Fortuna: 23 028 $ al 31/05/2024
Perfil
Christopher R.
Aker is currently working as the Secretary, Senior Vice President & General Counsel at Regulus Therapeutics, Inc. Prior to his current position, he worked as the Senior Director-Administration at Phenomix Corp.
from 2005 to 2011 and as the Senior Counsel at Sugen, Inc. from 2001 to 2003.
Mr. Aker holds a graduate degree from Santa Clara University and an undergraduate degree from the University of California, Davis.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
20/05/2024 | 10 056 ( 0.02% ) | 23 028 $ | 31/05/2024 |
Cargos activos de Christopher Aker
Empresas | Cargo | Inicio |
---|---|---|
REGULUS THERAPEUTICS INC. | Consejero General | 20/05/2011 |
Antiguos cargos conocidos de Christopher Aker.
Empresas | Cargo | Fin |
---|---|---|
Phenomix Corp.
![]() Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Director Administrativo | 01/02/2011 |
Sugen, Inc.
![]() Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Consejero General | 01/01/2003 |
Formación de Christopher Aker.
University of California, Davis | Undergraduate Degree |
Santa Clara University | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
REGULUS THERAPEUTICS INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Phenomix Corp.
![]() Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Sugen, Inc.
![]() Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Christopher Aker